Neuropsychopharmacological profile of remoxipride in comparison with clozapine

Polish Journal of Pharmacology

Volumn 49, Issue 1, 1997, Pages 5-15

  Skuza, Grazyna ^a   Rogóz, Zofia ^a   Wieczorek, Anna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

behavior; central effects; clozapine; remoxipride

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; CLOZAPINE; COCAINE; DEXAMPHETAMINE; DIZOCILPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PANAMESINE; QUINPIROLE; REMOXIPRIDE; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CATALEPSY; CENTRAL NERVOUS SYSTEM; CLIMBING; CONDITIONING; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG MECHANISM; GROOMING; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PSYCHOPHARMACOLOGY; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CATALEPSY; CLOZAPINE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; GROOMING; MICE; MOTOR ACTIVITY; RATS; RATS, WISTAR; REMOXIPRIDE; STEREOTYPED BEHAVIOR;

EID: 0030978853     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ahlenius S., Ericson E., Wijkström A.: Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats. J. Pharm. Pharmacol., 1993, 45, 237-239.
2. Bartoszyk G. D., Bender H. M., Hellmann J., Schnorr C., Seyfried C. A.: EMD 57445: a selective sigma receptor ligand with the profile of an atypical neuroleptic. CNS Drug Rev., 1996, 2, 175-194.
3. Bastianetto S., Perrault G., Sanger D. J.: Pharmacological evidence for the involvement of sigma sites in DTG-induced contralateral circling in rats. Neuropharmacology, 1995, 34, 107-114.
4. Bastianetto S., Rouquier L., Perrault G., Sanger D. J.: DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways. Neuropharmacology, 1995, 34, 281-287.
5. Bischoff S., Bruinik A., Krauss J., Schaub M., Vassout A.: In vivo and in vitro characterization of dopamine receptors in hippocampus and their pharmacological relevance. Pharmacopsychiatry, 1986, 19, 304-305.
6. Blaha C. D., Lane R. T.: Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci. Lett., 1987, 78, 199-204.
7. 3 receptor mRNA levels. Neuropharmacology, 1993, 32, 901-907.
8. Chouinard G., Annable L.: An early Phase II clinical trial of BW 234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology, 1984, 84, 282-284.
9. Clineschmidt B. V., Martin G. E., Bunting P. R., Papp N. L.: Central symphatomimetic activity of (+)-5-methyl-10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central symphatomimetic and apparent anxiolytic properties. Drug Dev. Res., 1982, 2, 135-145.
10. Costall B., Naylor R.: Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia (Berlin), 1975, 43, 69-74.
11. Coward D. M., Imperato A., Urwyler S., White T. G.: Biochemical and behavioral properties of clozapine. Pharmacology, 1989, 99, S6-S12.
12. Delini-Stula A., Morpurgo C.: Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in rats. Int. J. Neuropharmacol., 1986, 7, 391-394.
13. Deutch A. Y., Lee M. C., Iadarola M. J.: Regionally specific effects of atypical neuroleptic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci., 1992, 3, 332-341.
14. Deutsch S., Weizman A., Goldman M. E., Morihisa J. M. C.: The sigma receptor: a novel site implicated in psychosis and antipsychotic drug efficacy. Clin. Neuropharmacol., 1988, 11, 105-119.
15. Fritz P. M., DeHaven-Hudkins D. L., Fleissner L. C., Ford-Rice F. Y., Luttinger D.: σ Receptor binding affinity and inhibition of apomorphine-induced climbing. Eur. J. Pharmacol., 1993, 229-235.
16. Groves P. M., Rebec G. V.: Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs. Annu. Rev. Psychol., 1976, 27, 91-127.
17. Guinetdinov R. R., Bogdanov M. B., Kudrin V. S., Rayevsky K. S.: Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats. Neuropharmacology, 1994, 33, 215-219.
18. Guy W., Manov G., Wilson W. H., Ban T.A., Fjetland O. K., Manberg P. J., Dren A. T.: Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: a dose-range study Drug Dev. Res., 1983, 3, 245-252.
19. Hascoet M., Bourin M., Payeur R., Lombet A., Peglion J.-L.: Sigma ligand S 14905 and locomotor activity in mice. Eur. Neuropsychopharmacol., 1995, 5, 481-489.
20. Kelly P. H., Iversen S. D.: Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur. J. Pharmacol., 1976, 40, 45-56.
21. Köhler C., Hall H., Magnusson O., Lewander T., Gustafsson K.: Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiat. Scand., 1990, 82 (Suppl. 358), 2736.
22. Köhler C., Radesäter A. C., Karlsson-Boethius G., Bryske B., Widman M.: Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. J. Neural Transm. [Gen. Sect.], 1992, 87, 49-62.
23. Largent B. L., Wikstrom H., Snowman A. M., Snyder S. H.: Novel antipsychotic drugs share high affinity for a receptors. Eur. J. Pharmacol., 1988, 155, 345-347.
24. Litchfield J. T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 1949, 96, 99-113.
25. Magnusson O., Fowler C. J., Köhler C., Ögren S. O.: Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioral effects of substituted benzamide drugs. Neuropharmacology, 1986, 25, 187-197.
26. Maj J., Rogóz Z., Skuza G.: Locomotor hyperactivity induced by MK-801 in rats. Pol. J. Pharmacol. Pharm., 1991, 43, 449-458.
27. Maj J., Rogóz Z., Skuza G., Mazela H.: Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. Eur. J. Pharmacol., 1996, 315, 235-243.
28. 2 dopamine receptor agonists, and the influence of selective antagonists. Pharmacol. Biochem. Behav., 1986, 25, 249-253.
29. Ögren S. O.: Potential mechanisms underlying the atypical antipsychotic profile of remoxipride. In: Strategies for Studying Brain Disorders, Vol. 2, Schizophrenia, Movement Disorders and Age Related Cognitive Disorders. Eds. Palomo T., Archer T., Beninger R., Farrand Press, London, 1994, 85-94.
30. Ögren S. O., Archer T.: Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile. Psychopharmacology, 1994, 114, 383-391.
31. Ögren S. O., Goldstein M.: Phencyclidine-and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology, 1994, 11, 167-177.
32. Ögren S. O., Hall H., Köhler C., Magnusson O., Lindbom L. O., Angeby K., Florvall L.: Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur. J. Pharmacol., 1984, 102, 459-474.
33. 2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat. J. Neural Transm. [Gen. Sect.], 1993, 93, 187-203.
34. 2 receptors. Neuroscience, 1994, 61, 269-283.
35. Patrick S. L., Walker J. M., Perkel J. M., Lockwood M., Patrik R. L.: Increases in rat striatal extracellular dopamine and vacuous chewing produced by two sigma receptor ligands. Eur. J. Pharmacol., 1993, 231, 243-249.
36. Protais P., Costentin J., Schwartz J. C.: Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology, 1976, 50, 1-6.
37. Quirion R., Bowen W. D., Itzhak Y., Junien J. M., Mussacchio J. M., Rothman T. P., Su T. P., Tam S. W., Taylor D. P.: A proposal on the classification of sigma binding sites. Trends Pharmacol. Sci., 1992, 13, 85-86.
38. 4 receptors in the action and development of antipsychotic agents. Drugs, 1996, 51, 7-11.
39. 2 receptors. NeuroReport, 1995, 6, 329-332.
40. Schwarcz G. A., Halaris A., Dren A., Manberg P.: Open label evaluation of the novel antipsychotic compound BW 234U in chronic schizophrenics, Drug Dev. Res., 1985, 5, 387-393.
41. Seeman P., Van Tol H. H. M.: Dopamine receptor pharmacology. Trends Pharmacol. Sci., 1994, 15, 264-270.
42. 3) as a novel target for antipsychotics. Biochem. Pharmacol., 1992, 43, 659-666.
43. Tam S. W., Cook L.: σ-Opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]-SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc. Nat. Acad. Sci. USA, 1984, 81, 5618-5621.
44. 2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. J. Pharmacol. Exp. Ther., 1992, 263, 1167-1174.
45. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 1991, 350, 610-614.
46. Vasse M., Chagroui A., Protais P.: Climbing and stereo-typy behaviours in mice require the stimulation of D-1 receptors. Eur. J. Pharmacol., 1988, 148, 221-229.
47. Wadworth A. N., Heel R. C.: Remoxipride. A review of its pharmacodynamic properties and therapeutic potential in schizophrenia. Drugs, 1990, 40, 863-879.
48. Walker J. M., Bowen W. D., Walker F. O., Matsumoto R. R., De Costa B. Rice K. C.: Sigma receptors: biology and function. Pharmacol. Rev., 1990, 42, 355-402.
49. 2 agonist effects. Science, 1987, 236, 719-722.
50. Witkin J. M., Terry P., Menkel M., Hickey P., Potecorvo M., Ferkany J., Katz J. L.: Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl) hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J. Pharmacol. Exp. Ther., 1993, 266, 473-482.